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INTRODUCTION 
It is a chronic metabolic disorder which is characterized by 
hyperglycemia, hyperlipaemia, glycosuria, negative 
nitrogen balance and sometimes ketonemia that may lead 
to long term complication in a form of diabetic 
retinopathy, diabetic nephropathy, diabetic neuropathy and 
diabetic fetopathy or it is a group of metabolic disorders of 
carbohydrate metabolism in which glucose is 
underutilized, producing hyperglycemia resulting from a 
defect in 
I. Type 1 diabetes (beta cell destruction, usually leading to 
absolute insulin deficiency) 
A. Immune-mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin 
resistance with relative insulin deficiency to a 
predominantly insulin secretory defect with insulin 
resistance) 
III. Other specific types of diabetes 
IV Gestational diabetes mellitus 
Two features of the current classification of DM diverge 
from previous classifications. First, the terms insulin-
dependent diabetes mellitus (IDDM) and non-insulin-
dependent diabetes mellitus (NIDDM) are obsolete. Since 
many individuals with type 2 DM eventually require 
insulin treatment for control of glycemia, the use of the 
term NIDDM generated considerable confusion. A second 
difference is that age is not a criterion in the classification 
system. Although type 1 DM most commonly develops 
before the age of 30, an autoimmune beta cell destructive 
process can develop at any age. It is estimated that 
between 5 and 10% of individuals who develop DM after 
age 30 years have type 1 DM. Although type 2 DM more 
typically develops with increasing age, it is now being 
diagnosed more frequently in children and young adults, 
particularly in obese adolescents. 
A total of 57 million deaths occurred in the world during 
2008; 36 million (63%) were due to NCDs, principally 
cardiovascular diseases, diabetes, cancer and chronic 
respiratory diseases. Nearly 80% of these NCD deaths (29 
million) occurred in low- and middle-income countries. 
NCDs are the most frequent causes of death in most 
countries in the Americas, the Eastern Mediterranean, 
Europe, South-East Asia, and the Western Paciﬁ c. In the 
African Region, there are still more deaths from infectious 
diseases than NCDs. Even there, however, the prevalence 
of NCDs is rising rapidly and is projected to cause almost 
three-quarters as many deaths as communicable, maternal, 
perinatal, and nutritional diseases by 2020, and to exceed 
them as the most common causes of death by 2030. WHO 
projections show that NCDs will be responsible for a 
signiﬁcantly increased total number of deaths in the next 
decade. NCD deaths are projected to increase by 15% 
globally between 2010 and 2020 (to 44 million deaths). 
The greatest increases will be in the WHO regions of 
Africa, South-East Asia and the Eastern Mediterranean, 
where they will increase by over 20%. In contrast, in the 
European Region, WHO estimates there will be no 
increase. In the African Region, NCDs will cause around 
3.9 million deaths by 2020.  The regions that are projected 
to have the greatest total number of NCD deaths in 2020 
are South- East Asia (10.4 million deaths) and the Western 
Paciﬁc (12.3 million deaths) .Nearly 26 million Americans 
have diabetes, according to new estimates from the Centers 
for Disease Control and Prevention (CDC). In addition, an 
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estimated 79 million U.S. adults have prediabetes, a 
condition in which blood sugar levels are higher than 
normal, but not high enough to be diagnosed as diabetes. 
Prediabetes raises a person's risk of type 2 diabetes, heart 
disease and stroke. 
Diabetes affects 8.3 percent of Americans of all ages, and 
11.3 percent of adults aged 20 and older, according to the 
National Diabetes Fact Sheet for 2011. About 27 percent 
of those with diabetes—7 million Americans—do not 
know they have the disease. Prediabetes affects 35 percent 
of adults aged 20 and older. 
 It is an endocrine disorder, more than 100 million (6% of 
the population) of people world-wide are affected inspite 
of enormous facilities available to control its growth. Type 
2 diabetes is caused by two primary metabolic defects: 
progressive β-pancreatic cell dysfunction and insulin 
resistance. β-Cell dysfunction superimposed on insulin 
resistance leads to hyperglycaemia and subsequently to 
type 2 diabetes. Typically, at the time of diabetes 
diagnosis, nearly 50% of β -cell function has been lost and 
less than 60% of normal insulin sensitivity ispresent5. 
Diabetes is a chronic illness that requires continuing 
medical care and patient self-management education to 
prevent acute complications and to reduce the risk of long-
term complications.The lifestyle modification, diet and 
exercise of moderate intensity are used to improve insulin 
sensitivity and are recommended as an integral part of 
treatment of Type 2 diabetes. When the lifestyle 
modification, diet and exercise fails to maintain the 
adequate glycaemic control, oral hypoglycemic agents are 
introduced as a treatment approach.Oral Hypoglycemic 
Agents (OHAs) can be used either alone or in combination 
with other OHAs or insulin. The Canadian Diabetes 
Association 2003 Clinical Practice Guidelines for the 
Prevention and Management of Diabetes recommends a 
target hemoglobin A1C concentration of 6.5%or less for 
all patients with diabetes. Currently, there are five major 
classes of oral antidiabetic agents: sulphonylureas – insulin 
secretagogues that target β -cell dysfunction; metformin – 
a biguanide that reduces hepatic glucose production and 
improves insulin sensitivity, thiazolidinediones – insulin 
sensitizers that lower peripheral insulin resistance; _ -
glucosidase inhibitors – intestinal enzyme inhibitors that 
slow carbohydrate absorption; and meglitinides – rapid but 
short-acting, nonsulphonylurea secretagogues.The goal 
levels of diabetes related parameters during treatment is 
given. Insulin is also important in type 2 DM when blood 
glucose levels cannot be controlled by diet, weight loss, 
exercise and oral medications. Insulin is indicated in the 
following situations: 1) when diet and oral hypoglycaemic 
drugs fail to control hyperglycaemia and achieve therapy 
targets 2) diabetes during pregnancy when diet alone is 
inadequate, 3) when oral hypoglycaemic drugs are 
contraindicated, 4) during stressful conditions such as 
infection and surgery. 
METFORMIN 
Salient feature of Metformin pharmacological profile are- 
 It is a drug of choice for Type 2 DM. 
 It suppresses hepatic gluconeogenesis and glucose 
output, increases peripheral utilization of glucose and 
inhibits glycogenolysis. 
 It shows less hypoglycemia in comparision to others 
as a ADR. 
 It also causes Lactic acidosis,Vit B12 deficiency and 
abdominal discomfort as ADR 
GLIMIPERIDE 
 It is a third generation sulfonyl urea which  is a insulin 
secretagogue. 
 It increases insulin secretion by blocking ATP 
sensitive K-channel 
 Hpoglycemia and weight gain as a ADR is a major 
problem. 
 It is usually given in combination with metformin. 
 MATERIALS AND METHODS 
Animals 
Wistar albino rats (150–170 g) were obtained from Central 
Animal Facility,Jamia Hamdard and kept at 25±1 °C, 
55±5% humidity alongwith 12 h light/dark cycle. The 
animals were given standard pellet diet (Lipton rat feed, 
Ltd., Pune) and water ad libitum throughout the 
experimental period. The experiment was approved by the 
‘Institutional Animal Ethics Committee’. Both the drug 
pioglitazone and vitamin E were administered orally. 
Table 1: Details of animal used for this study 
Animal Rat (Rattus Norvegicus) 
Strain Wistar 
Weight 150mg 
Gender Male 
Total time duration  Six month 
Standard drug Metformin and Glimiperide 
Total no. of animal per 
group 
Six 
Work place Pharmacology research lab, IEC 
Group of Institution, Gr Noida 
Total no.of animal 30 
Total no. of group of 
animal 
Five 
 
Experimental Framework 
30 Wistar rats of either sex is taken.It is divided into 5 
groups with 6 rats in each group.The experimental study 
was carried out under controlled condition.Rat is procured 
from animal house ,CMJ university ,Meghalay.The rat  
was maintained on pellet feed and water ad libitum until 
the time of experiment.Animal was kept overnight fasting 
before the day of experiment. Diabetes was induced by 
stress . The drugs (metformin and glimiperide) was given 
to group  for 21 weeks.Glimperide is given in a dose of 
17.5 mg/day and metformin 200 mg/day. 
Table 2: Drugs with their trade name 
Drug Trade name 
Metfoprmin Glyciphage 
Glimiperide Glimi 
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TREATMENT SCHEDULE 
Table 3: Number of groups with their treatment schedule is presented below. 
RESULTS 
Animal group Parameter 
Body weight 
(Kg) 
HbA1c 
(%) 
FPG 
(mg/dl) 
PPG 
(mg/dl) 
Total 
Cholesterol 
(mg/dl) 
Serum 
Triglyceride 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
1 Normal 
control 
150 5.5 90 150 150 150 50 75 
2 Disease 
control 
175 8.0 180 250 200 175 30 150 
3 Glimeperide 
control 
160 7.0 120 200 190 165 35 125 
4 Metformin 
control 
155 6.5 110 180 185 160 40 115 
5 Glimeperide 
+ metformin 
control 
152 6.0 100 155 170 155 45 110 
 
 
 
 
Glycemic control 
It is seen in the  that those group who is under the 
treatment of Metformin and glimiperide have better poat 
prandial and fasting glycemic control while it is moderate 
in Metformin and least in glimiperide teated group.The 
untreated group i.e disease control have very high level of 
blood glucose. 
 
 
Glycosylated hemoglobin: - During the study there were 
significant differences were found in initial and final 
values of HbA1C levels of both groups. Though the 
HbA1C level was found to be reduced more significantly 
(P: 0.0001) patients treated with Metformin-
glimepirideThe glycosylated hemoglobin was found to be 
reduced. 
Total Cholesterol 
It is seen in the  that those group who is under the 
treatment of Metformin and glimiperide have lowest level 
of total cholesterol.while it is moderate in Metformin and 
higher in glimiperide teated group.The untreated group i.e 
disease control have very high level of blood cholesterol. 
Effects on Triglycerides 
It is seen that those group who is under the treatment of 
Metformin and glimiperide have lowest value of 
triglycerides, while it is moderate in Metformin and higher 
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Total 
Cholesterol 
Group Animal Drugs,route of administration,dose 
1 Normal  control No drug 
2 disease control Stress 
3 Glimeperide control Glimiperide(17.5 mg/kg,oral) in diabetic rat 
4 Metformin control  Metformin(200mg/kg/day,Oral)in diabetic rat+HFD+stress 
5 Glimeperide + metformin 
control 
Glimiperide(17.5mg/kg,oral)+Metformin(200 mg/kg/day,Oral) in diabetic rat 
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in glimiperide teated group.The untreated group i.e disease 
control have very high level of blood glucose.Although 
even combination of Metformin and glimiperide treated 
group have more blood triglyceride in comparision to 
normal control. 
Effects on HDL 
It is seen that Metformin and glimiperide treated group 
have lower level while it is moderate in Metformin and 
lesser in glimiperide teated group.The untreated group i.e 
disease control have highest level of HDL. 
Effects on LDL 
It is seen in the  that those group who is under the 
treatment of Metformin and glimiperide have lower level 
while it is moderate in Metformin and higher in 
glimiperide teated group.The untreated group i.e disease 
control have very high level of serum LDL. 
DISCUSSION                                                                                                                 
A conventional stepwise approach to diabetes therapy 
involves the use of a single oral agent titrated to maximum 
dosage, each of which targets a single pathological defect 
of type 2 DM as its primary mechanism of action, with the 
requirement of poor glycaemic control as an indication for 
the addition of a second oral agent. During the study it has 
been found that type 2 diabetes is more pronounced at the 
age of 44.26 ± 1.5yrs. while 58% of patients were found to 
be at the greater risk of hypertension or other 
cardiovascular complication. Treatment with metformin-
glimepiride orally simultaneously targets insulin resistance 
and insulin deficiency of type 2 diabetes, which may 
account for the greater effects on glycaemia. 
Indeed,metformin-glimepiride therapy produced greater 
mean changes from baseline in HbA1C.The greater mean 
changes from the baseline in case of fasting plasma 
glucose were found. But the statistical analysis using one 
way ANOVA followed by Dunnet test concludes that the 
drug treated group metformin glimiperide combinations 
were prescribed in patients with fasting plasma glucose 
more than 240.0 ± 16.65 mg/dl. While the better mean 
reductions were found in the FPG in patients of group. 
Furthermore, 29.41% of patients receiving metformin-
glimepiride therapy attained a final HbA1c of <6.0%. 
These results demonstrate that treatment with metformin-
glimepiride was efficacious in improving glycaemia by 
achieving therapeutic goals for HbA1C and fasting plasma 
glucose in patients with type 2 diabetes.  
The reductions in the blood sugar level were found due to 
the synergistic effect. The synergistic effect of both 
combinations may be due to the different mechanism of 
action of individual drugs in the both combination. 
Metformin decreases hepatic glucose production through 
inhibition of gluconeogenesis and possibly glycogenolysis 
and improves the peripheral insulin sensitivity.In diabetic 
patients there is an increased risk of cardiovascular 
complications followed by higher morbidity and mortality 
than in a nondiabetic population.Cardiovascular disease is 
2–3 times commoner in diabetics than in non-diabetics. 
Known risk factors are such as raised cholesterol, 
hypertension,, abdominal obesity, hyperinsulinemia, and 
degree of glycaemic control only partly explain the 
increased risk. In the present study more than 58% of 
patients were at the greater risk of cardiovascular diseases. 
The patients treated with Metformin-glimepiride 
combination resulted in the significantly reduction in the 
total cholesterol, serum triglyceride, and LDL cholesterol 
while helped to increased the HDL cholesterol throughout 
the study. So this combination can be considered as the 
best double combination to be prescribed in patients with 
increased cholesterol and triglyceride concentration. 
CONCLUSION 
From the data in results and discussion the present study 
concludes that the  combinations of  Metformin and 
glimepiride reduce the Glycosylated Hemoglobin 
level,fasting and post-prandialplasma glucose level 
significantly.. While the significant reduction in the total 
cholesterol,triglyceride and LDL cholesterol was also 
observed in the Metformin and glimepiride combination. It 
also significantly increased the HDL cholesterol levels . So 
the Metformin and glimepiride combination can be 
considered as the best possible two drug combination in 
patients with altered lipid profile. 
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